Abstract
This review examines the use of combinations of oral antiplatelet agents with oral anticoagulant agents for long-term secondary prevention in patients with cardiovascular diseases such as myocardial infarction (MI), mechanical valve replacement, coronary artery stent implantation, and chronic atrial fibrillation (AF).